Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
about
Progress of molecular targeted therapies for prostate cancersSipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.Current treatment strategies for castration-resistant prostate cancerThe AR dependent cell cycle: mechanisms and cancer relevance.
P2860
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase III data for abiraterone ...... ion-resistant prostate cancer.
@ast
Phase III data for abiraterone ...... ion-resistant prostate cancer.
@en
type
label
Phase III data for abiraterone ...... ion-resistant prostate cancer.
@ast
Phase III data for abiraterone ...... ion-resistant prostate cancer.
@en
prefLabel
Phase III data for abiraterone ...... ion-resistant prostate cancer.
@ast
Phase III data for abiraterone ...... ion-resistant prostate cancer.
@en
P2860
P1433
P1476
Phase III data for abiraterone ...... ion-resistant prostate cancer.
@en
P2093
Oliver Sartor
Sumanta Kumar Pal
P2860
P304
P356
10.1016/J.MATURITAS.2010.10.009
P577
2010-11-19T00:00:00Z